RxDoctor Payments DataLook up a doctor →

Tanuja Chitnis, MD

Neurology · Boston, MANPI 1376517078

Payments from drug & device makers

$4,451,232in general payments, 2019–2025

Across 186 payments — averaging $23,931 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1.6M
  • Genentech, Inc.$1.2M
  • Novartis Pharma AG$648K
  • Mallinckrodt Hospital Products Inc.$375K
  • E.r. Squibb & Sons, L.L.C.$367K
  • Mallinckrodt Enterprises LLC$80K
  • plus $177K from 13 others
$32,946in research payments, 2019–2025

Across 22 payments — averaging $1497.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • F. Hoffmann-la Roche AG$8K
  • Novartis$8K
  • Sanofi$6K
  • UCB, Inc.$6K
  • Novartis Pharma AG$5K
  • Biogen$960

What the payments were for

  • Consulting fees$169,30784%
  • Speaking & faculty fees$9,9415%
  • Travel & lodging$21,17310%
  • Food & beverage$1,9711%
  • Education$60%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,451,232 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$7,654
Medicare patients
31
Services billed
66

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab23$190,343
Plegridy PenPeginterferon Beta-1a18$150,410
TecfideraDimethyl Fumarate12$105,552
BetaseronInterferon Beta-1b12$100,810
AubagioTeriflunomide11$94,374
Dimethyl Fumarate31$31,601
Teriflunomide16$18,022
FingolimodFingolimod Hcl15$17,307
Baclofen44$1,711
Riluzole18$1,393
Modafinil22$876
AmantadineAmantadine Hcl11$793
Gabapentin30$656
Memantine Hcl12$527
Levetiracetam14$483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera$16,491$105,55212 claims
SanofiAubagio$52,028$94,37411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 761 neurology providers in Massachusetts.

Other neurology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →